We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+132.32%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$742M
AUM Growth
+$199M
Cap. Flow
+$27.6M
Cap. Flow %
3.72%
Top 10 Hldgs %
43.53%
Holding
99
New
34
Increased
28
Reduced
16
Closed
17

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$33.1M
2
RNAM
Avidity Biosciences
RNAM
+$17.6M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$14.8M
4
GUTS icon
Fractyl Health
GUTS
+$13.5M
5
BIIB icon
Biogen
BIIB
+$10.9M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$39M
2
VRNA
Verona Pharma
VRNA
+$33.9M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$20.5M
4
ETNB
89bio
ETNB
+$20M
5
SLNO
Soleno Therapeutics
SLNO
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 93.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDSX icon
76
Biodesix
BDSX
$220M
$375K 0.05%
49,607
-3,911
-7% -$30.1K
MBX
77
MBX Biosciences
MBX
$3.14B
$263K 0.04%
+15,000
New +$201K
ELVN icon
78
Enliven Therapeutics
ELVN
$3.92B
$219K 0.03%
10,675
+675
+7% +$13.6K
MLTX icon
79
MoonLake Immunotherapeutics
MLTX
$1.57B
$215K 0.03%
30,000
-52,023
-63% -$2.71M
ARCT icon
80
Arcturus Therapeutics
ARCT
$164M
$63.5K 0.01%
+3,445
New +$55.3K
NKTR icon
81
Nektar Therapeutics
NKTR
$2.39B
$20.8K ﹤0.01%
365
+19
+5% +$629
RCKTW icon
82
Rocket Pharmaceuticals Warrant
RCKTW
$149K
$4.11K ﹤0.01%
104,828
– –
AKRO
83
CALL
DELISTED
Akero Therapeutics
AKRO
– –
-25,000
Closed -$1.33M
CCOI icon
84
CALL
Cogent Communications
CCOI
$676M
– –
-500,000
Closed -$3.59M
ETNB
85
DELISTED
89bio
ETNB
– –
-2,037,087
Closed -$20M
GPCR icon
86
Structure Therapeutics
GPCR
$3.41B
– –
-175,636
Closed -$3.64M
HIMS icon
87
PUT
Hims & Hers Health
HIMS
$6.43B
– –
-50,000
Closed -$2.49M
MRUS
88
CALL
DELISTED
Merus
MRUS
– –
-382,500
Closed -$20.1M
MRUS
89
DELISTED
Merus
MRUS
– –
-741,972
Closed -$39M
NBIX icon
90
Neurocrine Biosciences
NBIX
$16.8B
– –
-162,969
Closed -$20.5M
NUVL
91
CALL
DELISTED
Nuvalent
NUVL
– –
-100,200
Closed -$7.65M
PFE icon
92
Pfizer
PFE
$143B
– –
-344,338
Closed -$8.35M
SGMT icon
93
Sagimet Biosciences
SGMT
$439M
– –
-37,539
Closed -$286K
SLNO
94
DELISTED
Soleno Therapeutics
SLNO
– –
-204,591
Closed -$17.1M
TRML
95
DELISTED
Tourmaline Bio
TRML
– –
-109,257
Closed -$1.75M
VRNA
96
DELISTED
Verona Pharma
VRNA
– –
-358,297
Closed -$33.9M
XNTK icon
97
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2.06B
– –
-200,000
Closed -$16.6M
ORKA
98
Oruka Therapeutics
ORKA
$5.82B
– –
-165,389
Closed -$1.85M
MTSR
99
DELISTED
Metsera Inc
MTSR
– –
-207,581
Closed -$5.91M
1 2 3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Silverarc Capital Management held 99 positions worth $742M, up 37% from $542M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Silverarc Capital Management deployed $27.6M of net new capital in Q3 2025, opening 34 new positions and adding to 28 existing holdings. Its largest new stake was Abivax: 539,704 shares worth $45.8M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier.

On the sell side, the largest reduction was UroGen Pharma, an estimated $7.99M trimmed.

  • Silverarc Capital Management's largest Q3 2025 buy was Abivax: 539,704 shares worth $45.8M.
  • Silverarc Capital Management added most to Avidity Biosciences in Q3 2025, an estimated $17.6M increase.
  • Silverarc Capital Management's biggest Q3 2025 reduction was UroGen Pharma, cutting an estimated $7.99M.
  • Silverarc Capital Management fully exited Merus in Q3 2025, selling an estimated $39M.
  • Silverarc Capital Management's ten largest holdings make up 44% of its $742M portfolio in Q3 2025.
  • Silverarc Capital Management opened 34 new positions and closed 17 in Q3 2025.
  • Silverarc Capital Management's portfolio value rose 37% quarter-over-quarter to $742M.

Based on Silverarc Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.